{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T23:17:58Z","timestamp":1790983078438,"version":"4.1.0"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Ivonescimab is a PD-1\/VEGF bispecific antibody that combines immune checkpoint blockade with anti-angiogenic activity. As PD-1\/VEGF-directed regimens enter routine solid-tumor care, rare toxicities at the interface of immune activation, endothelial injury, and thrombotic microangiopathy require careful case-level characterization.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>A 63-year-old man with stage IVB lung adenocarcinoma (cT1bN2M1c, with multiple extrathoracic rib metastases) received an ivonescimab-containing combination regimen consisting of three cycles of ivonescimab plus nab-paclitaxel and cisplatin, followed by chemotherapy alone after partial response. He developed fever, severe cholestatic liver injury, and KDIGO stage 3 acute kidney injury requiring temporary continuous renal replacement therapy. Serum creatinine peaked at 767 \u00b5mol\/L and subsequently normalized. Evolving anemia, thrombocytopenia, schistocytes, Coombs-negative hemolysis, and organ injury prompted evaluation for thrombotic microangiopathy. ADAMTS13 activity was 8.87% with a functional inhibitor of 1.8 BU\/mL, confirming acquired immune-mediated thrombotic thrombocytopenic purpura. The PLASMIC score was 5, reflecting intermediate clinical probability because active malignancy and MCV &amp;gt;90 fL lowered the score; definitive diagnosis therefore depended on ADAMTS13 testing. Treatment included corticosteroids, 10 sessions of DPMAS\/TPE support with transition to FFP-based plasma exchange once iTTP was recognized, and rituximab 500 mg weekly from April 17 to May 8, 2026. Caplacizumab was not used because it was unavailable locally. No platelet transfusions were administered; red blood cells and plasma were transfused as clinically indicated. ADAMTS13 activity increased to 23.82% and inhibitor titer decreased to 0.85 BU\/mL on the available follow-up test, but serial ADAMTS13 and complement measurements were not available. The patient had biochemical improvement and normalization of renal function.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This case highlights ADAMTS13 inhibitor-positive iTTP as a rare, actionable toxicity after ivonescimab-containing chemoimmunotherapy rather than proof of ivonescimab as the sole causal agent. The renal phenotype should be framed as severe but reversible AKI rather than dialysis-dependent renal failure. In patients receiving PD-1\/VEGF-directed combination therapy, thrombocytopenia with microangiopathic hemolysis and organ injury should trigger smear review, PLASMIC scoring, urgent ADAMTS13 testing, and early mechanism-directed therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1908239","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T05:37:55Z","timestamp":1785821875000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Acquired immune-mediated thrombotic thrombocytopenic purpura with severe cholestatic liver injury and reversible acute kidney injury after ivonescimab-containing chemoimmunotherapy: a case report and literature review"],"prefix":"10.3389","volume":"17","author":[{"given":"Qiqi","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Emergency, Beijing Electric Power Hospital of State Grid Corporation of China","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojing","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Emergency, Peking University People\u2019s Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Beijing Electric Power Hospital of State Grid Corporation of China","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxia","family":"Niu","sequence":"additional","affiliation":[{"name":"Department of Emergency, Beijing Electric Power Hospital of State Grid Corporation of China","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Emergency, Peking University People\u2019s Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)02722-3","article-title":"Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China","volume":"405","author":"Xiong","year":"2025","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.10613","article-title":"Ivonescimab plus chemotherapy in non-small cell lung cancer with EGFR variant: a randomized clinical trial","volume":"332","author":"Fang","year":"2024","journal-title":"JAMA"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/jth.15006","article-title":"ISTH guidelines for the diagnosis of thrombotic thrombocytopenic purpura","volume":"18","author":"Zheng","year":"2020","journal-title":"J Thromb Haemost"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(17)30026-1","article-title":"Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study","volume":"4","author":"Bendapudi","year":"2017","journal-title":"Lancet Haematol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009150","article-title":"Redefining outcomes in immune thrombotic thrombocytopenic purpura: an international working group consensus report","volume":"137","author":"Cuker","year":"2021","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/jth.15010","article-title":"ISTH guidelines for treatment of thrombotic thrombocytopenic purpura","volume":"18","author":"Zheng","year":"2020","journal-title":"J Thromb Haemost"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtha.2025.06.002","article-title":"2025 focused update of the 2020 ISTH guidelines for management of thrombotic thrombocytopenic purpura","volume":"23","author":"Zheng","year":"2025","journal-title":"J Thromb Haemost"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1806311","article-title":"Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura","volume":"380","author":"Scully","year":"2019","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-10-559211","article-title":"The role of rituximab in the management of patients with acquired thrombotic thrombocytopenic purpura","volume":"125","author":"Lim","year":"2015","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.109015","article-title":"Acquired thrombotic thrombocytopenic purpura associated with immune checkpoint inhibitors: a real-world study of the FDA adverse event reporting system","volume":"110","author":"Moore","year":"2022","journal-title":"Int Immunopharmacol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s40425-017-0224-7","article-title":"Ipilimumab-induced thrombotic thrombocytopenic purpura (TTP)","volume":"5","author":"King","year":"2017","journal-title":"J Immunother Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/2464619","article-title":"Thrombotic thrombocytopenic purpura due to checkpoint inhibitors","volume":"2018","author":"Youssef","year":"2018","journal-title":"Case Rep Hematol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13553","article-title":"Nivolumab-induced thrombotic thrombocytopenic purpura in a patient with anal squamous cell carcinoma: a lesson on hematologic toxicity from immunotherapy","volume":"25","author":"Gergi","year":"2020","journal-title":"Oncologist"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/trf.16117","article-title":"Refractory thrombotic thrombocytopenic purpura related to checkpoint inhibitor immunotherapy","volume":"61","author":"Lancelot","year":"2021","journal-title":"Transfusion"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.16035","article-title":"Immune checkpoint inhibitor-associated thrombotic thrombocytopenic purpura in a patient with metastatic non-small-cell lung cancer","volume":"13","author":"De Filippis","year":"2021","journal-title":"Cureus"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1177\/10781552211073883","article-title":"Thrombotic thrombocytopenic purpura associated with pembrolizumab","volume":"28","author":"Nelson","year":"2022","journal-title":"J Oncol Pharm Pract"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.871217","article-title":"Case report: thrombotic-thrombocytopenic purpura following ipilimumab and nivolumab combination immunotherapy for metastatic melanoma","volume":"13","author":"Mullally","year":"2022","journal-title":"Front Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/trf.17378","article-title":"Durable remission of thrombotic thrombocytopenic purpura in the setting of pembrolizumab therapy","volume":"63","author":"Kozak","year":"2023","journal-title":"Transfusion"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.2931-23","article-title":"Nivolumab-induced thrombotic thrombocytopenic purpura in patients with gastric tube cancer","volume":"63","author":"Yoshida","year":"2024","journal-title":"Intern Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-026-06907-3","article-title":"Thrombotic thrombocytopenic purpura as a complication of pembrolizumab: a case report and literature review","volume":"105","author":"Palega","year":"2026","journal-title":"Ann Hematol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.72247","article-title":"Thrombotic thrombocytopenic purpura in a patient with triple-negative breast cancer treated with PD-L1 inhibition and taxane chemotherapy","volume":"14","author":"Ke","year":"2026","journal-title":"Clin Case Rep"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0707330","article-title":"VEGF inhibition and renal thrombotic microangiopathy","volume":"358","author":"Eremina","year":"2008","journal-title":"N Engl J Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00081.2025","article-title":"Mechanisms of anti-VEGF therapy-induced kidney injury: current insights and future perspectives in combination with immune checkpoint inhibitors","volume":"329","author":"Uyl","year":"2025","journal-title":"Am J Physiol Renal Physiol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.1088031","article-title":"Drug-induced thrombotic microangiopathy: an updated review of causative drugs, pathophysiology, and management","volume":"13","author":"Mazzierli","year":"2022","journal-title":"Front Pharmacol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-11-611335","article-title":"Drug-induced thrombotic microangiopathy: a systematic review of published reports","volume":"125","author":"Al-Nouri","year":"2015","journal-title":"Blood"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1908239\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T05:37:56Z","timestamp":1785821876000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1908239\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,4]]},"references-count":27,"alternative-id":["10.3389\/fimmu.2026.1908239"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1908239","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,4]]},"article-number":"1908239"}}